ADMA
NASDAQ · Biotechnology
Adma Biologics Inc
$9.81
+0.31 (+3.21%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
—
1Y
-38.61%
YTD
-45.13%
Open$9.54
Previous Close$9.51
Day High$9.84
Day Low$9.45
52W High$20.46
52W Low$7.21
Volume—
Avg Volume2.38M
Market Cap2.00B
P/E Ratio11.82
EPS$0.71
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$17.86
Below
SMA 200
$17.61
Below
RSI (14)
42.2
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
11 analysts
Price Target
+259.0% upside
Current
$9.81
$9.81
Target
$35.22
$35.22
$21.76
$35.22 avg
$46.82
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 456.60M | 306.36M | 922.90M |
| Net Income | 131.49M | 79.40M | -95,808,796 |
| Profit Margin | 28.8% | 27.4% | -10.4% |
| EBITDA | 168.49M | 107.40M | -107,012,515 |
| Free Cash Flow | — | — | -83,155,340 |
| Rev Growth | +49.0% | +49.0% | +20.1% |
| Debt/Equity | 0.15 | 0.15 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |